DD Dec 2019 77.500 put

OPR - OPR Delayed Price. Currency in USD
10.25
0.00 (0.00%)
As of 10:21AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close10.25
Open10.25
Bid15.15
Ask15.90
Strike77.50
Expire Date2019-12-20
Day's Range10.25 - 10.25
Contract RangeN/A
Volume3
Open InterestN/A
  • Investopedia

    10 Bargain Blue Chips with Improving Growth Prospects

    Even as the market soars to new record highs, these stocks still have significant upside potential, per research by Bernstein.

  • Investopedia

    Profit Takers Abound as Stocks Pull Back

    U.S. stock prices fell by 1%. The market anticipates more European growth, while gold and silver are poised to rally.

  • 52-Week Company Lows
    GuruFocus.com

    52-Week Company Lows

    DuPont de Nemours, Exelon, Occidental Petroleum, Ventas, Plains All American Pipeline and CenterPoint Energy present buying opportunities Continue reading...

  • Hedge Funds Warming Up To DuPont de Nemours, Inc. (DD)
    Insider Monkey

    Hedge Funds Warming Up To DuPont de Nemours, Inc. (DD)

    "Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]

  • Bloomberg

    What ‘Dark Waters’ Reveals About Corporate Science

    (Bloomberg Opinion) -- A new movie, “Dark Waters,” shines a bright light on a group of dangerous chemicals that are likely in your bloodstream right now. It tells the true story of a polluter that manipulated research and kept evidence hidden from the public – and shows just how crucial it is that scientific evidence be produced by researchers free of conflicts of interest.The chemicals that drive the film’s drama, known as PFAS, are remarkably effective at repelling water and oil. They’re used to make familiar products such as Teflon, Scotchgard and Gore-Tex, and are found in the coating of pizza boxes and microwave-popcorn bags. Unfortunately, in recent years, they’ve also gained attention for their links to cancer, liver and thyroid disease, increased cholesterol, and depressed fertility. They’ve been found in the blood of almost every American ever tested, and they contaminate the water in communities across the U.S.“Dark Waters” focuses on how the chemical company DuPont manufactured Teflon in a West Virginia town, and in the process fouled the local drinking water with a PFAS compound. Over the course of the drama, viewers learn that DuPont hid much of what it knew about its effects. In 1981, for example, DuPont was informed by 3M (from which DuPont purchased much of its C8) that the chemical caused birth defects in rats; DuPont then learned of two apparent birth defects among children of its Teflon division employees. Both the PFAS-exposed babies and the rats were born with eye defects, making the link particularly alarming. But the firm never reported this in the scientific literature or revealed it to the public.When the first public concerns abound the compound emerged, DuPont did what too many corporations do: They took a page from Big Tobacco’s playbook and hired a firm to sow doubt about the scientific evidence. ChemRisk, whose top staff had consulted for cigarette manufacturers, produced a risk assessment with exactly the conclusion DuPont wanted: exposures around the plant were thousands of times lower than levels that cause illness.The film captures how a courageous attorney working virtually on his own was able to document DuPont’s coverup. Armed with those documents, the Environmental Protection Agency eventually issued its then largest-ever fine, and required DuPont to clean up the local water supply.Significantly, DuPont also agreed to fund a series of studies on C8’s effects on the plant’s workers and local residents. To ensure the research would be truly independent and credible, the two sides together selected scientists to direct the studies. The results were startling: C8 exposure increased the risk of testicular and kidney cancer, ulcerative colitis, thyroid disease, pregnancy-induced hypertension and elevated cholesterol. DuPont has since paid more than $600 million in compensation to thousands of people sickened with these conditions.As more studies document the wide range of toxic properties of PFAS compounds, manufacturers are rapidly eliminating the chemicals from their products, and lawmakers are eyeing legislation to clean up contaminated water systems. After hiring two product-defense consulting firms, Exponent and Gradient, to dispute the C8 studies, 3M settled a PFAS pollution claim made by the state of Minnesota for $850 million. But as the PFAS debacle has painfully made clear, the system through which scientific evidence is produced also needs to be cleaned up.First, corporations shouldn’t be allowed to sequester important scientific findings about the harms of their products. Stiff penalties could be applied when case reports of disease or the results of health-effects studies are not made public. The few corporations that get caught hiding data, like DuPont and 3M did, eventually pay large amounts to settle claims. But this is too late for people made sick or whose environment was damaged.Second, the public shouldn’t believe the results of studies done by product-defense consulting firms. After all, their business model is to provide clients with the ammunition to sway public opinion, slow regulation and defeat court claims. If they did otherwise, they would never be hired again.And finally, the model of scientific investigation highlighted in “Dark Waters” should be rule rather than the exception. To some extent, this is the model of the Health Effects Institute, a research organization that commissions research into the health effects of air pollution, set up and funded jointly by the Environmental Protection Agency and motor vehicle manufacturers. But for the most part, corporations have been reluctant to fund research over which they have no control.We badly need a new model for production of the evidence necessary to protect the public. When government agencies consider potentially harmful exposures and activities, from vaping to opioids to glyphosate to payday loans, they should insist the regulated industries provide data produced by unconflicted scientists. In this paradigm, the firms responsible for the potential harm would be required to pay for the research, but the studies would be conducted by scientists without conflicts of interest, under provisions that ensure their complete independence. Only then will we have confidence in the integrity of the results.To contact the author of this story: David Michaels atTo contact the editor responsible for this story: Tracy Walsh at twalsh67@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.David Michaels is a professor at the Milken Institute School of Public Health at George Washington University. He served as assistant secretary of labor for the Occupational Safety and Health Administration from 2009 to 2017, and is the author of the forthcoming book "The Triumph of Doubt: Dark Money and the Science of Deception."For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.

  • GuruFocus.com

    Stocks That Fell to 3-Year Lows in the Week of Nov. 22

    DuPont de Nemours, Simon Property Group, Expedia and Molson Coors Brewing present buying opportunities Continue reading...

  • Don't Race Out To Buy DuPont de Nemours, Inc. (NYSE:DD) Just Because It's Going Ex-Dividend
    Simply Wall St.

    Don't Race Out To Buy DuPont de Nemours, Inc. (NYSE:DD) Just Because It's Going Ex-Dividend

    Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

  • DuPont Recommends Rejection of TRC Capital's "Mini-Tender" Offer
    PR Newswire

    DuPont Recommends Rejection of TRC Capital's "Mini-Tender" Offer

    WILMINGTON, Del., Nov. 21, 2019 /PRNewswire/ -- DuPont (DD) today announced that it has been notified of an unsolicited "mini-tender" offer by TRC Capital Investment Corporation to purchase up to 2 million shares, or approximately 0.27 percent of outstanding shares, of DuPont's common stock at $64.75 per share, which was approximately 4.27 percent below the closing share price of DuPont's common stock on Nov. 15, 2019 ($67.64), the last trading day prior to the date of TRC Capital's mini-tender offer, and approximately 0.46 percent below the closing share price of DuPont common stock on Nov. 20, 2019 ($65.05), the day prior to this release.

  • Top Materials Stocks for December 2019
    Investopedia

    Top Materials Stocks for December 2019

    The materials sector includes companies engaged in the discovery, development, and processing of raw materials, which are used across many other sectors and industries. Materials stocks include manufacturers of products as varied as plastic, fertilizer, paper, concrete, metals, and more. Some prominent names in the materials sector include Dupont de Nemours Inc. (DD), Ecolab Inc. (ECL), and Dow Inc. (DOW).

  • Bloomberg

    DuPont Movie ‘Very Damaging,’ Analyst Says After Sneak Preview

    (Bloomberg) -- The movie “Dark Waters” about the effect of deadly chemicals in West Virginia is “very damaging” for DuPont de Nemours Inc., Wall Street analysts at Fermium Research wrote in a report before its theatrical debut on November 22.Analyst Frank Mitsch -- who watched a sneak preview -- thinks that “Dark Waters” will probably be a hit film and may cast a shadow over DuPont shares and the entire chemical industry. The movie focuses on DuPont and Chemours Co.’s already-settled litigation over perfluorooctanoic acid production.DuPont’s shares fell as much as 2.7% on Friday in New York, while broader market inched higher.“We can see a scenario where interest in DD from individual investors (85% institutional ownership according to Bloomberg) dissipates, though also a broader concern for the chemicals sector given the negative portrayal,” he added.One positive, though, is that Chemours wasn’t mentioned at all during the movie, Mitsch said. The focus was solely on DuPont and it’s possible that the average moviegoer will likely “walk away disgusted” only with DuPont.For their part, investors are probably more interested in DuPont due to the prospect for merger and acquisition activity. The company has been exploring the divestiture of assets, Mitsch wrote, and if a deal occurs it’s possible that the negatives from the movie may subside.“Our hot-take is the film is a near-term negative, but when the first blockbuster M&A transaction gets announced, it may fade into the background,” the analyst concluded.To contact the reporter on this story: Aoyon Ashraf in Toronto at aashraf7@bloomberg.netTo contact the editors responsible for this story: Brad Olesen at bolesen3@bloomberg.net, Scott SchnipperFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Thomson Reuters StreetEvents

    Edited Transcript of DD.N earnings conference call or presentation 31-Oct-19 12:00pm GMT

    Q3 2019 Dupont De Nemours Inc Earnings Call

  • GuruFocus.com

    US Indexes Close Mostly Higher Wednesday

    S&P; 500 gains 0.07% Continue reading...

  • Moody's

    DuPont de Nemours, Inc. -- Moody's announces completion of a periodic review of ratings of DuPont de Nemours, Inc.

    Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of DuPont de Nemours, Inc. New York, November 11, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of DuPont de Nemours, Inc. and other ratings that are associated with the same analytical unit. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.

  • 7 Stocks Poised to Rise as Market Enters Best Stretch in 8 Decades
    Investopedia

    7 Stocks Poised to Rise as Market Enters Best Stretch in 8 Decades

    The November to January period historically offers the strongest stock market returns, and these stocks may be poised to ride that seasonal pattern.

  • Chemical Stock Earnings Due on Nov 7: APD, ESI, TROX & ICL
    Zacks

    Chemical Stock Earnings Due on Nov 7: APD, ESI, TROX & ICL

    Let's take a look at how these chemical companies are poised ahead of their earnings release.

  • Should You Be Worried About DuPont de Nemours, Inc.'s (NYSE:DD) 7.4% Return On Equity?
    Simply Wall St.

    Should You Be Worried About DuPont de Nemours, Inc.'s (NYSE:DD) 7.4% Return On Equity?

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

  • GuruFocus.com

    US Indexes Close Higher Friday and for the Week

    S&P; 500 up 22.19% for the year Continue reading...

  • Barrons.com

    It’s Been a Tough Year in Agriculture. Farm-Supply Stocks Take Different Paths.

    Two companies that supply farmers— (CTVA) and (FMC)—are on different paths as investors assess their quarterly results. The stock (ticker: CTVA) fell 4% Thursday, worse than the 0.5% decline of the Dow Jones Industrial Average. For Corteva, “we had previously thought there was a possibility that domestic corn yields might be significantly impaired in 2019 due to adverse weather conditions that led to a very late planting season,” wrote Zekauskas in a Friday research report.

  • Barrons.com

    DuPont Stock ‘Is Too Cheap’ and Has Catalysts

    DuPont stock is up a second straight day after reporting third-quarter numbers. Some on Wall Street see opportunity in the company’s nutrition business is sold or spun off.

  • DuPont Rises 4%
    Investing.com

    DuPont Rises 4%

    Investing.com - DuPont (NYSE:DD) rose by 4.05% to trade at $68.57 by 10:31 (14:31 GMT) on Friday on the NYSE exchange.

  • GuruFocus.com

    US Indexes Close Lower Thursday

    S&P; 500 up 2% for October Continue reading...

  • MarketWatch

    DuPont says its nutrition & biosciences business got a boost from plant-based meat demand

    One of the hottest food trends featured in the earnings of specialty chemicals company DuPont de Nemours Inc. on Thursday. The company said it's nutrition & biosciences (N&B) business saw a boost in food and beverage volumes driven by gains in specialty proteins from growing demand for plant-based meats. On the company's earnings call with analysts, Chief Operating Officer Marc Doyle said the company's plant-based meat business is "relatively small today," but that it is expected to grow in the double digits. Alternative meat has become a big business in the U.S., as companies' like Beyond Meat Inc. and Impossible Meat are introducing their products at more restaurants and fast-food outlets, as well as on grocery shelves. DuPont's N&B business is just one of four business segments, along with electronics & imaging, transportation & industrial and safety & construction. DuPont shares were up 1% Thursday, but have fallen 13% in 2019, while the S&P 500 has gained 21%.

  • DuPont (DD) Beats on Q3 Earnings & Sales, Narrows EPS View
    Zacks

    DuPont (DD) Beats on Q3 Earnings & Sales, Narrows EPS View

    DuPont (DD) gains from higher pricing, portfolio actions and cost control amid a challenging macroeconomic environment in Q3.

  • Barrons.com

    DuPont’s Earnings Beat the Street. They Also Point to a Stronger World Economy.

    DuPont’s results beat the Wall Street consensus by a couple of pennies. The better news is that some DuPont businesses, an indicator of the outlook for the global economy, are showing early signs of improvement.

  • DuPont's (DD) Q3 Earnings and Sales Beat Estimates
    Zacks

    DuPont's (DD) Q3 Earnings and Sales Beat Estimates

    DuPont's (DD) Q3 adjusted earnings of 96 cents per share surpassed the Zacks Consensus Estimate of 95 cents.